Transurethral Incision with Transverse Mucosal Realignment (TUITMR)
TUITMR combines incision of a nonobliterative bladder-neck contracture or vesicourethral anastomotic stenosis with endoscopic advancement and fixation of adjacent mucosa. It is an evolving technique intended to cover the opened scar with viable tissue. The original 19-patient retrospective series reported encouraging short-term patency, but does not establish superiority, prevention of fibrosis or a negligible incontinence risk.[1]
See BNC, VUAS, and standard incision.
Operative concept
The following describes the published approach; it is not a validated protocol for all posterior stenoses.[1]
- Assess the lumen cystoscopically and establish safe wire access into the bladder. Dilate sufficiently for controlled instrumentation when appropriate.
- Incise the stenotic scar to open the lumen while protecting adjacent structures. Do not perform endoluminal treatment of a completely obliterated posterior stenosis; avoid deep incisions at 6 and 12 o'clock.[2]
- Use transurethral suturing access to advance adjacent healthy bladder mucosa across the incision and secure the realignment. The described instrument platform includes the JNW UrTrac sheath, RD180 suturing device, and Ti-Knot fastener.
- Confirm patency, hemostasis and drainage; individualize catheter management. The index study assessed patency by passage of a 17 Fr flexible cystoscope at 4 months.
Mucosal coverage is the rationale. The clinical data do not prove that it prevents scar re-formation, eliminates adjunct-related risks from other aspects of care, or reliably improves outcomes in radiated tissue.
Published evidence
| Index study characteristic | Abramowitz 2021 |
|---|---|
| Design | Retrospective, 19 patients, one surgeon |
| Case mix | 53% VUAS, 47% BNC; 32% previously irradiated |
| Follow-up | Median 6 months; included patients with at least 4 months |
| Initial success | 17/19 (89%) |
| After repeat treatment | 19/19 (100%) |
| Incontinence and major complications | No new incontinence or major complications reported; small sample and short observation limit inference |
These are results from the index cohort, not expected outcomes for every patient. Radiation-subgroup effectiveness cannot be established from this small mixed series. Durable benefit, reproducibility and comparative safety require stronger evidence.[1]
Comparison with established treatment
The 2024 systematic review of 40 endoscopic VUAS studies and 1,452 patients estimated pooled success at 72.8% (95% CI 64.4–79.9%), falling to 62.9% (53.6–71.4%) after adjustment for publication bias. It does not show that 90% of patients need repeat intervention within two years. Variation in treatment, follow-up and success definitions prevents a valid ranking of TUITMR against these pooled results.[3]
The Nealon no-injection incision cohort reported 82.1% patency after one procedure and 94.3% after a second at median 12 months, but it is not a TUITMR comparator. Separate case-series percentages do not establish greater patency or less SUI with mucosal realignment.[4]
Clinical positioning
Guidelines support established endoscopic options for nonobliterative posterior stenoses and reconstruction for selected refractory disease. They do not establish TUITMR as routine first-line therapy or prescribe it after a fixed number of failures. Consider it within specialist discussion of the available evidence, anatomy and alternatives. Mitomycin C for posterior stenosis should remain within a clinical trial under EAU guidance, and posterior urethral stents are discouraged.[2]
Posterior drug-coated balloon treatment is also off-label. Berg's 141-patient retrospective comparison reported HR 0.40 (95% CI 0.19–0.87), whereas Patel's 319-patient series included only 59 posterior stenoses and had median follow-up of 5.7 months. In that posterior subgroup, estimated one-year functional recurrence-free survival was 75.8% and anatomic recurrence-free survival 59.4%, with wide confidence intervals. These are different endpoints in different cohorts; neither study directly compares DCB with TUITMR.[5][6]
Videos
References
1. Abramowitz DJ, Balzano FL, Ruel NH, Chan KG, Warner JN. "Transurethral Incision With Transverse Mucosal Realignment for the Management of Bladder Neck Contracture and Vesicourethral Anastomotic Stenosis." Urology. 2021;152:102-108. doi:10.1016/j.urology.2021.02.035
2. European Association of Urology. EAU Guidelines on Urethral Strictures. 2026. Disease management in males, sections 6.3.5–6.3.6. Guideline.
3. Delchet O, Nourredine M, González Serrano A, et al. "Post-Prostatectomy Anastomotic Stenosis: Systematic Review and Meta-Analysis of Endoscopic Treatment." BJU International. 2024;133(3):237-245. doi:10.1111/bju.16141
4. Nealon SW, Bhanvadia RR, Badkhshan S, et al. "Transurethral Incisions for Bladder Neck Contracture: Comparable Results Without Intralesional Injections." Journal of Clinical Medicine. 2022;11(15):4355. doi:10.3390/jcm11154355
5. Berg EK, Mehmedovic S, Askari D, et al. "Efficacy of Drug-Coated Balloon Dilation vs. Endoscopic Standard Treatment in Posterior Urethral Stenosis: A Real-World Comparative Study." Urology. 2025. doi:10.1016/j.urology.2025.07.034
6. Patel HV, Erickson BA, Abbasi B, et al. "Early Real-World Experience With Optilume® Drug-Coated Balloon for Anterior Urethral Strictures and Posterior Urethral Stenoses." Urology. 2025. doi:10.1016/j.urology.2025.10.025